title: Femoral artery recanalisation with percutaneous angioplasty and segmentally enclosed plasminogen activator.
abstract: To establish whether re-occlusion of the femoral artery could be prevented, in 6 consecutive patients undergoing percutaneous transluminal angioplasty (PTA) for superficial femoral artery occlusion the recanalised segment was isolated, with a 7-French double-balloon catheter. 5 mg recombined human tissue-type plasminogen activator (rt-PA) and 1000 IU heparin were then infused into the enclosed space for 30 minutes, followed by intravenous heparin for 24 hours. At 10 and 30 days all 6 patients had evidence of recanalisation and remission of symptoms. Mean ankle-arm pressure index improved by 72% at 24 hours, by 118% at 10 days, and by 103% at 30 days after the procedure. No patients had major complications. Treatment of superficial femoral artery occlusions by PTA with rt-PA and intravenous heparin seems to prevent rethrombosis.
authors.affiliation: Department of Clinical Physiology/Nuclear Medicine, Bispebjerg Hospital, Copenhagen, Denmark.
authors.forename: B
authors.initials: B
authors.lastname: Jørgensen
authors.forename: K H
authors.initials: KH
authors.lastname: Tønnesen
authors.forename: J
authors.initials: J
authors.lastname: Bülow
authors.forename: J D
authors.initials: JD
authors.lastname: Nielsen
authors.forename: M
authors.initials: M
authors.lastname: Jørgensen
authors.forename: P
authors.initials: P
authors.lastname: Holstein
authors.forename: E
authors.initials: E
authors.lastname: Andersen
mesh_terms: D000368:Aged; D000800:Angioplasty, Balloon / Q000379:methods*; D001157:Arterial Occlusive Diseases / Q000097:blood / Q000628:therapy*; D002408:Catheters, Indwelling; D003131:Combined Modality Therapy; D005263:Femoral Artery; D005340:Fibrinogen / Q000032:analysis; D006493:Heparin / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008875:Middle Aged; D010960:Plasminogen Activators / Q000008:administration & dosage* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D012008:Recurrence; D013927:Thrombosis / Q000517:prevention & control*; D013997:Time Factors; D014654:Vascular Patency / Q000187:drug effects
chemical_list: D011994:Recombinant Proteins; D005340:Fibrinogen; D006493:Heparin; D010960:Plasminogen Activators